ArticleFrontiers in cardiovascular medicine2026
Polymeric mitral valve replacement in rheumatic heart disease: hemodynamic and early clinical outcomes from a dedicated sub-analysis of the India Surgical Trial.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatic heart disease (RHD) is a leading cause of cardiovascular morbidity in low- and middle-income countries (LMICs), disproportionately affecting young patients and women of childbearing age. Current valve options-mechanical and bioprosthetic-result in significant challenges in these populations, including the need for intensive anticoagulation monitoring or accelerated structural deterioration. This study evaluates a novel polymeric heart valve designed to overcome these limitations. Methods: The India Mitral Surgical Trial (CTRI/2023/02/049837) was a prospective, multicenter, single-arm trial involving 67 adult patients requiring mitral valve replacement. Patients were implanted with the polymer surgical mitral valve and followed for one-year with safety and hemodynamic assessments. Vitamin K antagonists were administered for a target INR of 2.5. This subgroup analysis focuses on patients with RHD. Results: The RHD subgroup, included 49 patients with a mean age of 39 years, of whom 33 (67%) were female. The trial achieved 100% technical success defined as successful implantation of the study valve with immediate satisfactory valve function and no intraoperative valve-related complications. At one-year, all-cause mortality for the RHD subgroup was 10.2% with no valve-related deaths and no incidence of structural valve deterioration or valve reintervention. The mitral inflow gradient decreased from 9.9 ± 5.1 mmHg at baseline to 4.2 ± 1.5 mmHg at discharge and 4.4 ± 1.7 mmHg at 1 year while the echo defined effective orifice area increased from 0.9 ± 0.5 cm Conclusion: The polymeric valve demonstrated an acceptable safety profile and excellent hemodynamic stability at one-year. Further studies are needed to confirm durability and study anticoagulation reduction. Polymeric valves may be a promising option for patients with RHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.